Int. J. Mol. Sci. 2015, 16(8), 17514-17534; doi:10.3390/ijms160817514
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine
Vittorio Simeon 1,†,*
, Katia Todoerti 1,†, Francesco La Rocca 1, Antonella Caivano 1, Stefania Trino 1, Marta Lionetti 2, Luca Agnelli 2
, Luciana De Luca 1, Ilaria Laurenzana 1, Antonino Neri 2 and Pellegrino Musto 3
, Luciana De Luca 1, Ilaria Laurenzana 1, Antonino Neri 2 and Pellegrino Musto 31
Laboratory of Pre-Clinical and Translational Research, Reference Cancer Center of Basilicata, Scientific Institute of Hospitalization and Treatment, Rionero in Vulture 85028, Italy
2
Department of Clinical Sciences and Community Health, University of Milan and Hematology, Fondazione CÃ Granda, Ospedale Maggiore Policlinico, Milan 20122, Italy
3
Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture 85028, Italy
â€
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Sabrina Angelini
Received: 13 June 2015 / Revised: 21 July 2015 / Accepted: 22 July 2015 / Published: 30 July 2015
(This article belongs to the Special Issue Pharmacogenetics and Personalized Medicine)
Abstract
Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) which may represent a valid model for high-risk MM. This disease is associated with a very poor prognosis, and unfortunately, it has not significantly improved during the last three decades. New high-throughput technologies have allowed a better understanding of the molecular basis of this disease and moved toward risk stratification, providing insights for targeted therapy studies. This knowledge, added to the pharmacogenetic profile of new and old agents in the analysis of efficacy and safety, could contribute to help clinical decisions move toward a precision medicine and a better clinical outcome for these patients. In this review, we describe the available literature concerning the genomic characterization and pharmacogenetics of plasma cell leukemia (PCL). View Full-TextKeywords:
plasma cell leukemia; molecular profiling; risk stratification; pharmacogenetics; precision medicine
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Simeon, V.; Todoerti, K.; La Rocca, F.; Caivano, A.; Trino, S.; Lionetti, M.; Agnelli, L.; De Luca, L.; Laurenzana, I.; Neri, A.; Musto, P. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. Int. J. Mol. Sci. 2015, 16, 17514-17534.
Related Articles
Article Metrics
Comments
[Return to top]
Int. J. Mol. Sci.
EISSN 1422-0067
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert